Pharmaceuticals
Cure Genetics Announced Promising Safety and Efficacy Data of CAR-NKT Product CGC729 for RCC at ASGCT 2024
SUZHOU, China, May 23, 2024 /PRNewswire/ -- On May 10, 2024, Cure Genetics announced the safety and efficacy data of their CAR-NKT product, CGC729, for patients with relapsed and refractory metastatic renal cell carcinoma (R/R mRCC) in an oral presentation at the 27th Annual Meeting of the Americ...
2024-05-23 23:00
2855
Laekna Announces FDA Approval for the Phase III Clinical Trial Protocol of LAE002 (Afuresertib) PLUS LAE001 for the Treatment of Prostate Cancer
SHANGHAI and WARREN, N.J., May 23, 2024 /PRNewswire/ -- Laekna, Inc. (2105.HK), a science-driven, clinical-stage biotechnology company, announced that the company has received approval from the U.S. Food and Drugs Administration for the protocol of the phase III clinical trial of LAE002 (afureser...
2024-05-23 20:42
2429
111, Inc. Announces First Quarter 2024 Unaudited Financial Results
* Turned to Quarterly Operational Profitability for the First Time * Operating Expenses as a Percentage of Revenues Decreased 120 Basis Points YoY to 5.8% * Achieved Positive Operating Cash Flow SHANGHAI, May 23, 2024 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading...
2024-05-23 16:43
4179
Nona Biosciences Announces Global License and Option Agreement with AstraZeneca for Monoclonal Antibody to be Developed into Novel Tumor Targeted Therapies
CAMBRIDGE, Mass., May 22, 2024 /PRNewswire/ -- Nona Biosciences, a global biotechnology company providing a total solution from "Idea to IND" (I to ITM), ranging from target validation and antibody discovery through preclinical research, announced today that it has entered into a license agreemen...
2024-05-23 07:23
2099
Aiming for New Quality Productivity, Aiding in Reaching the Summit of Global Innovative Pharmaceuticals
Fully Human Antibody Development Platform—NeoMab Bio Officially Opens in Suzhou SUZHOU, China, May 22, 2024 /PRNewswire/ -- On May 22, 2024, NeoMab Biotechnology (Suzhou) Co., Ltd. celebrated its grand opening in Suzhou Industrial Park (BioBAY). This marks a significant milestone that will furthe...
2024-05-22 22:38
2381
Ractigen Therapeutics Secures FDA Fast Track Designation for RAG-01, a First-in-Class saRNA Therapy
SUZHOU, China, May 21, 2024 /PRNewswire/ -- Ractigen Therapeutics, a pioneering developer of small activating RNA (saRNA) therapeutics, proudly announces that its flagship program, RAG-01, has been granted Fast Track Designation (FTD) by the U.S. Food and Drug Administration (FDA). This notable a...
2024-05-21 20:00
2194
Cali Biosciences Announces Publication of Successful Phase 2 Study Results in Hernia
SAN DIEGO, May 21, 2024 /PRNewswire/ -- Cali Biosciences Co., Ltd. (hereinafter referred to as "Cali Biosciences"), a biotechnology company dedicated to the research and development of innovative drugs, announced publication of "CPL‑01, an investigational long‑acting ropivacaine, demonstrates saf...
2024-05-21 17:52
1442
Simcere Phar-maceuticals Presented Six Studies on Sanbexin® at ESOC 2024
NANJING, China, May 21, 2024 /PRNewswire/ -- The 10th European Stroke Organization Congress (ESOC), held inBasel, Switzerland from May 15 to 17, 2024 , showcased six studies on Sanbexin® (Edaravone and Dexborneol Concentrated Solution for Injection) and a new dosage form of sublingual tablets unde...
2024-05-21 15:52
1957
GC Biopharma/Novel Pharma's Sanfilippo Syndrome Treatment Obtains FDA IND Clearance
YONGIN, South Korea, May 21, 2024 /PRNewswire/ -- GC Biopharma (006280. KS) and Novel Pharma have announced that the U.S. FDA has cleared the investigational new drug (IND) application for their jointly developed MPSIIIA (Sanfilippo Syndrome Type A) treatment, GC1130A. With this FDA clearance,...
2024-05-21 15:12
1884
ZYMFENTRA™ (infliximab-dyyb) demonstrated long-term efficacy and safety profile of maintenance treatment through two years for adults with moderately to severely active Crohn's disease and ulcerative colitis
* Findings from the extended LIBERTY studies and associated post-hoc analysis support the long-term efficacy and safety of ZYMFENTRA™, the first and only FDA-approved subcutaneous infliximab[1],[2] * Data from a post-hoc analysis of the LIBERTY-CD study showed that, despite affecting drug lev...
2024-05-21 12:01
2297
HaemaLogiX welcomes former Australian Federal Minister for Health Professor the Hon Greg Hunt to the company board as Non-Executive Director
SYDNEY, May 20, 2024 /PRNewswire/ -- HaemaLogiX Ltd, a clinical stage biotech developing novel immunotherapies for patients with blood cancers and B-cell diseases, is pleased to announce the appointment of Professor the Hon Greg Hunt, former Australian Federal Minister for Health, to the HaemaLog...
2024-05-20 18:00
2588
GC Biopharma/Novel Pharma's Sanfilippo Syndrome Treatment Obtains FDA IND Approval
YONGIN, South Korea, May 20, 2024 /PRNewswire/ -- GC Biopharma (006280. KS) and Novel Pharma announced that its jointly developed MPS IIIA 'GC1130A' treatment has received FDA IND approval. With this approval, development of 'GC1130A' is expected to accelerate with multinational clinical trial...
2024-05-20 14:07
2108
Qilian International plans to adjust industrial investment
JIUQUAN, China, May 17, 2024 /PRNewswire/ -- Qilian International Holdings Group Limited (NASDAQ: QLI) ("Qilian" or the "Company"), a pharmaceutical and chemical products manufacturer headquartered inChina, today announced: In the past two years, Qilian International Holdings Group Limited has en...
2024-05-17 22:00
6343
Full-Life Technologies Announces Appointment of Mark S. de Jong, PhD, as Chief Technical Officer
GEMBLOUX, Belgium, May 16, 2024 /PRNewswire/ -- Full-Life Technologies (Full-Life), a fully integrated global radiotherapeutics company, today announced the appointment ofMark S. de Jong, PhD, to the newly created position of Chief Technical Officer (CTO). Dr. de Jong, joins Full-Life with 43 yea...
2024-05-17 08:00
1906
EHA 2024 | Results from Five Studies of Ascentage Pharma's Key Drug Candidates Selected for Presentations at 2024 European Hematology Association Hybrid Congress
SUZHOU, China and ROCKVILLE, Md., May 15, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that the latest results from five studies have been ...
2024-05-16 09:03
2476
Ractigen Therapeutics Receives IND Approval from China's NMPA to Initiate Phase 1 Clinical Trials for RAG-17 in SOD1-ALS Patients
SUZHOU, China, May 15, 2024 /PRNewswire/ -- Ractigen Therapeutics, a clinical-stage pharmaceutical company committed to developing pioneering therapies, today announces that the Center for Drug Evaluation (CDE) ofChina's National Medical Products Administration (NMPA) has approved the Investigat...
2024-05-15 20:00
2124
Novosis Putty Sets the Stage for U.S. Market Success with Promising Clinical Results
SEOUL, South Korea, May 14, 2024 /PRNewswire/ -- CGBio, a leading medical device company, announced a significant clinical results demonstrating a 100% interbody fusion success rate at 52 weeks for its innovative bone substitutes, "Novosis" and "Excelos Inject," which have been published in the '...
2024-05-14 20:00
2603
Mabwell Announces Clinical Trial Progress of 9MW2821 in Triple-Negative Breast Cancer
SHANGHAI, May 13, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, announced the progress of the clinical study of its novel Nectin-4-targeting ADC (R&D code: 9MW2821) for triple-negative breast cancer. Based on 9MW2821's curren...
2024-05-13 22:00
2334
Caliway to Present the Latest Clinical Advancements at 2024 BIO International Convention
NEW TAIPEI CITY, May 11, 2024 /PRNewswire/ -- Caliway Biopharmaceuticals (Caliway) is pleased to announce its participation to share the latest clinical advancements at the upcoming 2024 BIO International Convention onWednesday, June 5th, at 11:45 a.m. PDT. The presentation will take place in Com...
2024-05-11 15:14
4150
Single-Cell Multi-Omics Analysis of IASO Bio's Equecabtagene Autoleucel in the Treatment of Autoimmune Diseases of the Central Nervous System Published in Science Immunology
SHANGHAI, NANJING, China, and SAN JOSE, Calif., May 10, 2024 /PRNewswire/ -- On May 10, 2024, the impactful international academic journal, Science Immunology, a sub-journal ofScience, published a research paper titled "Single-cell analysis of anti-BCMA CAR T cell therapy in patients with central...
2024-05-11 10:16
4752
Week's Top Stories
Most Reposted
Agoda Launches Agoda Impact Lab at ASEAN Tourism Forum
[Picked up by 320 media titles]
2026-01-29 15:06
Wonder Raises USD 12 Million Venture Debt from HSBC Innovation Banking to Drive Growth and Expansion
[Picked up by 318 media titles]
2026-02-02 10:00
Agoda Launches Open-Source API Agent to Simplify MCP Server Integrations
[Picked up by 310 media titles]
2026-01-27 13:00
Nokia Strengthens Edge AI Capabilities Through Strategic Collaboration with Blaize on Hybrid Inference Solutions Across Asia Pacific Regions
[Picked up by 294 media titles]
2026-01-27 18:00
Singapore Airshow 2026 Milestone Edition: 20 Years of Shaping the Aerospace Landscape as Asia-Pacific Drives Global Growth
[Picked up by 284 media titles]
2026-02-01 19:35